^
    Back
    Association details:
    Biomarker:RAC1 P29S
    Cancer:Melanoma
    Drug:PLX4720 (BRAF inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    New
    Source:
    Cancer Cell
    Title:

    RAC1P29S Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy Resistance

    Excerpt:
    In contrast, the RAC1 genotype had a significant effect when animals were treated with the BRAF inhibitor PLX4720. Although RAC1WT tumors were generally stable or regressed, RAC1P29S tumors were clearly able to grow under PLX4720 therapy.
    DOI:
    10.1016/j.ccell.2019.05.015